江豐電子(300666.SZ):芯創科技擬引入核心員工對其進行增資
格隆匯10月17日丨江豐電子(300666.SZ)公佈,公司控股子公司寧波江豐芯創科技有限公司(“芯創科技”)擬引入核心員工對芯創科技進行增資,以充分調動相關業務核心骨幹的工作積極性,促進芯創科技的業務持續快速發展。核心員工擬向芯創科技出資合計311.052萬元,擬認繳芯創科技本次新增註冊資本111.09萬元,佔此次增資完成後芯創科技註冊資本總額的10.00%。
芯創科技現有股東,即江豐電子和VERSA CONN CORP.均放棄對芯創科技上述新增註冊資本的優先認繳出資權。此次增資完成後,芯創科技仍是公司的控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.